Kynam Capital Management, LP Celldex Therapeutics, Inc. Transaction History
Kynam Capital Management, LP
- $1.28 Billion
- Q2 2024
A detailed history of Kynam Capital Management, LP transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Kynam Capital Management, LP holds 3,388,967 shares of CLDX stock, worth $141 Million. This represents 9.76% of its overall portfolio holdings.
Number of Shares
3,388,967
Previous 2,900,000
16.86%
Holding current value
$141 Million
Previous $122 Million
3.05%
% of portfolio
9.76%
Previous 12.77%
Shares
11 transactions
Others Institutions Holding CLDX
# of Institutions
195Shares Held
63.4MCall Options Held
206KPut Options Held
176K-
Wellington Management Group LLP Boston, MA8.08MShares$336 Million0.05% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$195 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.74MShares$156 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.33MShares$139 Million2.17% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.17MShares$132 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.95B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...